Status:
UNKNOWN
Treatment Effect According to Timing of Administration of DWP14012 40 mg
Lead Sponsor:
Konkuk University Medical Center
Collaborating Sponsors:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Erosive Esophagitis
Eligibility:
All Genders
19-75 years
Phase:
NA
Brief Summary
The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.
Detailed Description
Subjects will provide written informed consent for study participation and then undergo appropriate screening. Subjects who meet the inclusion criteria and none of the exclusion criteria will be rando...
Eligibility Criteria
Inclusion
- Adults between 19 and 75 years old based on the date of written agreement
- Those who have been diagnosed with erosive esophagitis of LA Grade A-D on the upper gastrointestinal endoscopy
- Those who experienced symptoms of heartburn or acid regurgitation within the last 7 days
Exclusion
- Those who have undergone gastric acid suppression or gastric, esophageal surgery
- Those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT04888819
Start Date
February 1 2021
End Date
December 31 2021
Last Update
May 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Konkuk University Medical Center
Seoul, South Korea